BOSTON & MONTREAL, November 04, 2025--enGene Holdings Inc. ("enGene" or the "Company") (Nasdaq: ENGN), a clinical-stage, ...
The field of oncology has been profoundly impacted by malignant solid tumours, representing a significant challenge in healthcare. While strides have been ...
An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.
On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that the first patient has been ...
The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).
Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...
Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...
Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.
The phase 3 POTOMAC trial tested durvalumab added to BCG in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
A genetic test helps identify women at higher risk of breast cancer after early-stage lesions, enabling more personalized ...
BCG failure is much less common than previously thought in non-muscle invasive bladder cancer, so is adding a checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback